Glucocorticoid use is associated with an increased risk of hypertension
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Patients with RA are frequently treated with glucocorticoids (GCs), but evidence is conflicting about whether GCs are associated with hypertension. The aim of this study was to determine whether GCs are associated with incident hypertension in patients with RA. METHODS: A retrospective cohort of patients with incident RA and without hypertension was identified from UK primary care electronic medical records (Clinical Practice Research Datalink). GC prescriptions were used to determine time-varying GC use, dose and cumulative dose, with a 3 month attribution window. Hypertension was identified through either: blood pressure measurements >140/90 mmHg, or antihypertensive prescriptions and a Read code for hypertension. Unadjusted and adjusted Cox proportional hazards regression models were fitted to determine whether there was an association between GC use and incident hypertension. RESULTS: There were 17 760 patients in the cohort. A total of 7421 (42%) were prescribed GCs during follow-up. The incident rate of hypertension was 64.1 per 1000 person years (95% CI: 62.5, 65.7). The Cox proportional hazards model indicated that recent GC use was associated with a 17% increased hazard of hypertension (hazard ratio 1.17; 95% CI: 1.10, 1.24). When categorized by dose, only doses above 7.5 mg were significantly associated with hypertension. Cumulative dose did not indicate a clear pattern. CONCLUSION: Recent GC use was associated with incident hypertension in patients with RA, in particular doses ≥7.5 mg were associated with hypertension. Clinicians need to consider cardiovascular risk when prescribing GCs, and ensure blood pressure is regularly monitored and treated where necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Additional studies have corroborated these findings, linking even low dose glucocorticoid use (prednisone 2.5-7.5 mg/day) to increased risks of cardiovascular disease (9), severe infections (10), hypertension (11), diabetes (12), osteoporosis and fractures (13, 14), and increased overall mortality with concurrent type 2 diabetes mellitus (15).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [11]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667
Aviña‐Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. (2008) · Arthritis Care & Research · doi:10.1002/art.24092 · Cited by 1,462
Agca, R., Heslinga, S. C., Rollefstad, S., Heslinga, M., McInnes, I. B., Peters, M. J. L., Kvien, T. K., Dougados, M., Radner, H., Atzeni, F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209775 · Cited by 1,380
The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients
Westreich, D., & Greenland, S. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws412 · Cited by 1,276
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century
Symmons, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.7.793 · Cited by 646
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604
van Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
Sokka, T., Toloza, S., Cutolo, M., Kautiainen, H., Makinen, H., Gogus, F., Skakic, V., Badsha, H., Peets, T., Baranauskaite, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2591 · Cited by 476
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
Naranjo, A., Sokka, T., Descalzo, M. A., Calvo-Alén, J., Hørslev-Petersen, K., Luukkainen, R. K., Combe, B., Burmester, G. R., Devlin, J., Ferraccioli, G., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2383 · Cited by 467
Meune, C., Touze, E., Trinquart, L., & Allanore, Y. (2009) · Rheumatology · doi:10.1093/rheumatology/kep252 · Cited by 431
Cited by
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“In the second study with > 17 000 patients with RA but without hypertension at the time of diagnosis, GC use was associated with an 44% increased risk of hypertension (238).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Autoimmune diseases and atherosclerotic cardiovascular disease
Porsch, F., & Binder, C. J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01045-7 · Cited by 163
“promote hypertension 81 .”
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Bergstra, S. A., Sepriano, A. R., Kerschbaumer, A., van der Heijde, D. M. F. M., Caporali, R. F., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J. E., Takeuchi, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223358 · Cited by 131
Metadata
- Authors
- Costello, R. E., Yimer, B. B., Roads, P., Jani, M., & Dixon, W. G.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Corresponding author
- Costello, Ruth E
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-27
- Volume
- 60
- Issue
- 1
- Pages
- 132-139
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- PMC
- PMC7785301
- OpenAlex
- W3022267584
- Cited by
- 64
- References
- 30
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 17 · 2023: 9 · 2022: 7 · 2021: 5
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Lara D. Veeken (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, cc-by)
- Funders
- Centre for Epidemiology Versus Arthritis (21755)
- National Institute for Health Research Manchester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- glucocorticoids, hypertension, rheumatoid arthritis, hypertension incidence, glucocorticoid dose, cumulative dose, cardiovascular risk, blood pressure monitoring, antihypertensive prescribing
- MeSH terms
- Antihypertensive Agents, Arthritis, Rheumatoid, Blood Pressure Determination, Female, Glucocorticoids, United Kingdom, Humans, Hypertension, Male, Middle Aged, Retrospective Studies, Bias, Incidence, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucocorticoid use is associated with an increased risk of hypertension. https://app.cochat.ai/papers/10.1093/rheumatology/keaa209
- The paper
- Costello, R. E., Yimer, B. B., Roads, P., Jani, M., & Dixon, W. G. (2021). Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology. https://doi.org/10.1093/rheumatology/keaa209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

